TITUSVILLE, N.J., Oct. 30, 2018 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved INVOKANA ® ...
Johnson & Johnson JNJ announced that the FDA has extended the review timeline for a supplemental new drug application (sNDA) with respect to its SGLT2 inhibitor, Invokana. The sNDA seeks the ...
Janssen announced data from three real-world analyses for Invokana (canagliflozin) in adults with type 2 diabetes. The first was a retrospective observational study (n=16,613) of adults with type 2 ...
Forbes contributors publish independent expert analyses and insights. I report the latest in health, nutrition, wellness and healthy travel. A new treatment option will soon be available to people ...
INVOKANA (canagliflozin) 100mg and 300mg tablets The FDA has approved Janssen Pharmaceuticals' Invokana tablets for the treatment of type 2 diabetes. Invokana belongs to a new class of diabetes drugs ...
The diabetes drug Invokana, recently adopted by Nova Scotia's pharmacare program, is now the subject of a national class-action lawsuit. Court documents filed at the Ontario Superior Court of Justice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback